Overexpression of c-erbB-2 mRNA and/or c-neu oncoprotein is a predictor for metastases from colorectal cancer

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 1023-1026

  Yang, Jia Lin ^a   Yu, Yan ^a   Markovic, Boban ^b   Russell, Pamela J ^a   Crowe, Philip J ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

C erbB 2 mRNA; C neu; Colerectal cancer; Dukes' staging; Immunohistochemistry; In situ hybridization; Metastasis

Indexed keywords

MESSENGER RNA;

ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE C ERB; ONCOGENE NEU; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL;

EID: 0030935923     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Fidler IL and Hart IR: Biological diversity in metastatic neoplasms: origins and implications. Science 217: 998-1003, 1982.
2. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal tumor development. N Engl J Med 319: 525-532, 1988.
3. Pavelic ZP, Pavelic L, Kuvelkar R, et al: High c-myc protein expression in benign colorectal lesions correlates with the degree of dysplasia. Anticancer Res 12: 171-175, 1992.
4. Kapitanovic S, Spaventi R, Kusic B, et al: c-erbB-2/neu in colorectal carcinoma: a potential prognostic value? Eur J Cancer 29A: 170, 1992.
5. Levine AJ, Momand J and Finlay AC: The p53 tumour suppressor gene. Nature 351: 453-455, 1991.
6. Marshall CJ: Tumour suppressor genes. Cell 64: 313-326, 1991.
7. Leone A, Flatow U, King CR, et al: Reduced tumour incidence, metastatic potential, and cytokine responsivcness of nm23-transfected melanoma cells. Cell 65: 25-35, 1991.
8. Kapitanovic S, Spaventi R, Poljak L, et al: High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters. Cancer Detect Prevent 75: 97-101, 1994.
9. Omori K: DNA content and c-erbB-2 oncoprotein expression in hepatic metastases from colorectal carcinoma-in relation to clinicopathologic findings and prognosis. Japanese J Surgery 92: 1469-1479, 1991.
10. Pavelic ZP, Pavelic L, Lower EE, et al: c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue, invasive and non-invasive breast carcinoma. Cancer Res 52: 2597-2602, 1992.
11. Yonemura Y, Ninomiya I, Yamaguchi A, et al: Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res 57: 1034-1038, 1991.
12. Meltzer SJ, Ahnen DJ, Battifora, et al: Protooncogene abnormalities in colon cancers and adenopolyps. Gastroenterol 92:1174-1180, 1987.
13. Yang JL, Russell PJ, Crowe PJ, et al: Higher expression of oncoproteins c-myc, c-erbB-2/neu, PCNA and p53 in metastasising colorectal cancer than in non-metastasising tumours. Ann Surg Oncol 3:574-579, 1996.
14. Zhau HE, Pisters LL, Hail CL, et al: Bio-markers associated with prostate cancer progression. J Cellular Biochem-Suppl 19: 208-216, 1994.
15. Goyette MC, Cho K, Fasching CL, et al: Progression of colorectal cancer is associated with multiple tumour suppressor gene defects but inhibitions of tumourigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 12: 1387-1395, 1992.
16. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744, 1996.
17. Markovic B, Wu ZH, Chesterman CN, et al: Quantitation of Fc gamma RII mRNA in platelets and megakaryoblastic cell lines by a new method of in situ hybridization. J Immunol Methods 172: 105-114, 1994.
18. Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: a laboratory mannual (2nd ed). Cold Spring Harbor Laboratory Press, USA, 1989, pp 6.30-6.31.
19. Erba HP, Gunning P and Kedes L: Nucleotide sequence of the human gamma cytoskeletal actin mRNA; anormalous evolution of vertebrate non-muscle actin genes. Nucleic Acid Res 14: 5275-5294, 1986.
20. Forster AC, McInnes JL, Skingle DC, et al: Non radioactive hybridisation of probes prepared by the chemical labelling of DNA and RNA with a novel reagent. photobiotin. Nucleic Acid Res 13: 745-761, 1985.
21. Ahlgren JD: Chemotherapy. In: Colorectal cancer (Wanebo HJ, ed). St. Louis, Mosby, 1993, pp 523-539.
22. Borg A, Tandon AK, Sigurdsson H, et al: Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337, 1990.
23. Berchunk A, Kamel A, WhiKaker R, at al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091, 1990.
24. Kern JA, Schwartz D, Nordberg JA, et al: p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184-5191, 1990.
25. Kameda T, Yasui W, Yoshida K, et al: Expression of ERB2 in human gastric carcinomas: relationship between p185erbB2 expression and the gene amplification. Cancer Res 50: 8002-8009, 1990.
26. Weidner U, Peter S, Strohmeyer T, et al: Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res 50: 4504-4509, 1990.
27. Yu D and Hung MC: Expression of activated ras net oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6: 1991-1996, 1991.
28. Guy CT, Webster MA, Schauer M, et al: Expression of the neu protooncogcne in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578-1082, 1992.
29. Lazaris AC, Theodoropoulos GE, Anastassopoulos P, et al: Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Hislopathol 10: 661-668, 1995.
30. Tsioulias GJ, Muto T, Morioka Y, et al: erbB-2 gene expression in colorectal cancer. Japan J Exp Med 60: 343-349, 1990.
31. Gum R, Wang S-W, Lengyel E, et al: Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res 15: 1167-1172, 1995.
32. Verde P, Boast S, Franze A, et al: An upstream enhancer and a negative element in the S' flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res 16: 10699-10715, 1988.
33. Trggvason K, Hoyhtya M, and Salo T: Proteolytic degradation of extracellular matrix in tumour invasion. Biochim Biophys Acta 907: 191-217, 1987.
34. LioKa L, Goldfarb R, Brundage R, et al: Effect of plasminogen activator (urokinase). plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629-4636, 1981.
35. Salo T, Liotta L, Keski-Oja J, et al: Secretion of basement collagen degrading enzyme and plasminogen activator by transformed cells-Role in metastasis. Int J Cancer 30: 669-673, 1982.
36. Jessup JM: Tumor markers: Prognostic and therapeutic implications. In: Colorectal cancer (Wanebo HJ, ed). St. Louis, Mosby, 1993, pp 106-129.
37. Yang J-L, Crowe PJ, Russell PJ, et al: DNA flow-cytometric analysis in colorectal cancer: A comparison of metastasizing and nonmetastasizing tumours. J Gastroenterol Hepatol 11: 319-324, 1996.